Latest news with #DurvalumabSolutionforInfusion
Business Standard
14 hours ago
- Business
- Business Standard
Stock Alert: Tata Tech, HCL Tech, Railtel Corp, Tejas Networks, AstraZenca Pharma
Securities in F&O Ban: Glenmark Pharma, Hindustan Copper and RBL Bank are banned from F&O trading on 15 July 2025. Upcoming Results: GM Breweries, HDB Financial Services, HDFC Life Insurance, Himadri Special Chemicals, ICICI Lombard General Insurance, ICICI Prudential Insurance, Just Dial will declare their results alter today. Stocks to Watch: HCL Technologies consolidated net profit declined 10.77% to Rs 3,843 crore on 0.34% increase in revenue from operations to Rs 30,349 crore in Q1 FY26 over Q4 FY25. Railtel Corporation of India has received the work order worth Rs 2.64 crore from East Central Railway for provision of Kavach (indigenous train collision avoidance system) on low density railway track in 607 km of East Central Railway. Tejas Networks reported consolidated net loss of Rs 193.87 crore in Q1 FY26 compared with net profit of Rs 77.48 crore in Q1 FY25. Revenue from operations fell 87.08% YoY to Rs 201.98 crore in Q1 June 2025. AstraZeneca Pharma India has received permission from the Central Drugs Standard Control Organisation (CDSCO), Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 m. Tata Technologies reported 9.84% decline in consolidated net profit to Rs 170.28 crore on 3.22% drop in net sales to Rs 1244.29 crore in Q1 FY26 over Q4 FY25. Brigade Enterprises board has considered and approved the issuance on non-convertible debentures (NCDs) on a private placement basis in one or more tranches for an aggregate amount of up to Rs 1,500 crore.
Business Upturn
a day ago
- Business
- Business Upturn
AstraZeneca Pharma gets CDSCO approval to import and sell Imfinzi for additional indication
AstraZeneca Pharma India Ltd. has received approval from the Central Drugs Standard Control Organisation (CDSCO) to import and sell Durvalumab Solution for Infusion (Imfinzi) for an additional indication in India. The approval covers two dosage forms: 120 mg/2.4 ml and 500 mg/10 ml. As per the new indication, Imfinzi can be used in combination with gemcitabine and cisplatin as a neoadjuvant treatment, followed by single-agent Imfinzi as an adjuvant treatment after radical cystectomy. This is indicated for adult patients diagnosed with muscle invasive bladder cancer (MIBC). With this clearance, AstraZeneca can proceed to market Imfinzi for this indication in India, pending any additional regulatory approvals that may be required. In the meantime, AstraZeneca Pharma India shares closed at ₹9,194.50 on July 14. The stock opened at ₹9,200.00 and touched an intraday high of ₹9,303.00 and a low of ₹9,161.00. The company's 52-week high stands at ₹10,691.00, while the 52-week low is ₹6,220.00. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
&w=3840&q=100)
Business Standard
02-07-2025
- Business
- Business Standard
AstraZeneca Pharma pops 4% on CDSCO nod to import Durvalumab solution
AstraZeneca Pharma share price: Pharmaceutical company AstraZeneca Pharma share price was buzzing in trade on Wednesday, July 2, 2025, with the stock rising up to 3.83 per cent to an intraday high of ₹9,239.25 per share. At 12:31 PM, AstraZeneca Pharma share price continued to trade near day's high levels, up 3.28 per cent at ₹9,190. In comparison, BSE Sensex was trading 0.19 per cent lower at 83,535.28 levels. What triggered the up move in AstraZeneca Pharma share price? AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India. The Central Drugs Standard Control Organisation (CDSCO) granted permission to import and distribute Durvalumab Solution for Infusion (120 mg/2.4 ml and 500 mg/10 ml) for an additional indication. In an exchange filing, AstraZeneca Pharma said, 'This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.' The new approval allows Durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This is followed by maintenance treatment with Durvalumab and olaparib in cases of mismatch repair proficient (pMMR) endometrial cancer. The development enables AstraZeneca Pharma to market the drug in India for the newly approved indication, subject to further statutory approvals, if required. Track Stock Market LIVE Updates About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid-19 vaccine Leveraging data science and artificial intelligence (AI), AstraZeneca claims to boost the success rates and efficiency of its research and development (R&D) processes. The market capitalisation of AstraZeneca Pharma is ₹22,988.75 crore, according to BSE. The company falls under the BSE500 index. The 52-week high of AstraZeneca share price is ₹10,653.05, while its 52-week low is ₹6,222.35.
